Drug Topics

APRIL 28, 2024

In case you missed it, this week we had news about bird flu, remote continuous glucose monitoring, new atrial fibrillation care initiatives, and more.

184

184

STAT

APRIL 28, 2024

MorphoSys is dealing with an emerging safety issue related to pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis, STAT has learned. Physicians involved with MorphoSys’ completed Phase 3 study have reported multiple cases of palebresib-treated patients who rapidly progressed from myelofibrosis, a cancer affecting the bone marrow, to acute myeloid leukemia, a more aggressive and deadlier type of blood cancer, according

135

135

Pharmacy Times

APRIL 28, 2024

Vincent Young, MD, PhD, shares takeaways from Peggy Lillis Foundation's 2024 National C diff Advocacy Summit.

149

149

STAT

APRIL 28, 2024

As countries resume final negotiations on Monday for a landmark pandemic agreement intended to help prevent and rapidly respond to the next inevitable pandemic, I’m getting a sense of déjà vu. Why? The draft text has watered down intellectual property (IP) obligations in an attempt to achieve compromise on this issue. Diluting international obligations to achieve consensus is reminiscent of the limited waiver of one international patent obligation for Covid vaccines after two ye

Vaccines 115

Vaccines 115

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmaceutical Technology

APRIL 28, 2024

Artificial intelligence tools can be used for infection control through facial recognition systems designed to identify proper face mask use within hospitals.

Hospitals 119

Hospitals 119

pharmaphorum

APRIL 28, 2024

Pfizer has said it will launch its just-approved haemophilia B gene therapy Beqvez with a warranty programme that will provide “greater certainty” to payers, after setting a price directly in line with a rival treatment.

111

111

pharmaphorum

APRIL 28, 2024

Report from Evaluate shows growth in the orphan drugs sector is slowing down, in part as pharma and payers’ attention has refocused on treatments for more widespread conditions like obesity

110

110

Med Ed 101

APRIL 28, 2024

Meningococcal Disease Background Meningococcal disease is a severe, life-threatening illness that may manifest as meningitis, bacteremia, or bacteremic pneumonia. Even with antibiotic treatment, mortality due to invasive disease is 10-15%. Up to 20% of persons who become ill with invasive meningococcal disease may experience life-long disabilities, such as loss of limbs, deafness, cognitive deficits, and […] The post Meningococcal Prophylaxis – CDC Recommendations and Updates appeare

52

52

Roots Analysis

APRIL 28, 2024

Rare kidney diseases are a group of conditions, with at least 150 different disorders falling into this category. Kidney disorders are known to have a serious impact on the general kidney function, often lowering its ability to filter out waste and fluids from the blood, maintaining blood pressure, hemoglobin levels and electrolyte balance. Kidney disorders can either be short-term ( acute kidney injury ) or lifelong ( chronic ).

Insurance Coverage 40

Insurance Coverage Insurance FDA 40

BioPharm

APRIL 28, 2024

Key strategies for accelerating development and manufacturing and development timelines to bring drugs to market faster and give developers a competitive advantage.

40

40

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA